

REC Ref No.	IRAS No.	Name of Trial	Target Number of Participants Available?	Recruitment Target	Target Date To Recruit Participants Available?	Date Agreed To Recruit Target Number of Participants	Total Number of Participants Recruited at The Agreed Target Date	Date Study Closed to Recruitment	Recruitment Total	RTT Met?	Recruitment Closure Reason
14/WA/1118	159836	Pathos	Number Agreed	3	Date Agreed	20/02/2019	7	20/02/2019	7		Recruitment Finished
15/LO/1192	183464	A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses.	Number Agreed	2	Date Agreed	31/10/2019	4	26/04/2019	4		Recruitment Finished
15/LO/1538	188226	A study to evaluate the effectiveness and safety of Exablate transcranial MRgFUS thalamotomy treatment of medication refractory essential tremor subjects	Number Agreed	10	Date Agreed	13/02/2019	17	13/02/2019	17		Recruitment Finished
15/LO/1680	185421	Post Market Clinical Follow-Up Evaluation of BioPoly RS Partial Resurfacing Patella Implant	Number Agreed	5	Date Agreed	01/10/2019	0	01/10/2019	0		Recruitment Finished
15/NE/0406	186547	MNA-3521-011 - A First-in-Human, multi-centre, open-label, Phase 1 clinical study with RNA oligonucleotide drug MTL-CEBPA to investigate its safety and tolerability in patients with advanced liver cancer (OUTREACH)	Range Agreed	5	Date Agreed	31/12/2019	1	31/12/2019	1		Recruitment Finished
15/SC/0003	154916	An Open-Label, Multicenter, Phase 1/2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B cell Lymphomas.	Number Agreed	3	Not Available / Not Agreed			10/06/2019	7		Recruitment Finished
15/SC/0359	173940	M13-694: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fall	Number Agreed	6	Date Agreed	01/01/2019	4	01/01/2019	4		Recruitment Finished
15/SC/0409	183061	SEQUOIA (DARPIN) - OPHT 4170 (AMD)	Number Agreed	10	Date Agreed	03/06/2019	0	03/06/2019	0		Recruitment Finished
15/WM/0392	180166	Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer	Number Agreed	3	Date Agreed	01/03/2019	0	30/06/2019	0		Recruitment Finished
15/YH/0434	185622	GS-US-313-1580	Number Agreed	2	Date Agreed	01/06/2019	0	01/06/2019	0		Withdrawn By Host
16/EE/0386	208339	A Multicentre, Randomised, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5- Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of E	Number Agreed	5	Date Agreed	31/01/2019	5	31/01/2019	5		Recruitment Finished
16/EM/0382	210424	A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction.	Number Agreed	2	Date Agreed	29/03/2019	2	15/02/2019	2		Recruitment Finished
16/EM/0465	214926	INCYTE, Efficacy and Safety of INCB054828 in Urothelial Cancer	Number Agreed	1	Date Agreed	30/09/2019	2	30/09/2019	2		Recruitment Finished
16/LO/0422	198606	SRA737-02	Number Agreed	2	Date Agreed	31/03/2019	0	31/03/2019	0		Recruitment Finished
16/SC/0390	190073	Efficacy and safety of ofatumumab vs teriflunomide in RMS (OMB2301)	Number Agreed	4	Date Agreed	01/05/2019	0	01/05/2019	0		Recruitment Finished

16/SC/0600	209261	Combined Phase 2b/3, Double blind, Randomised, Placebo-Controlled Studies Evaluating the Efficacy and safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease	Number Agreed	2	Date Agreed	31/03/2019	1	31/03/2019	1		Recruitment Finished
16/SC/0653	215441	A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	Number Agreed	4	Date Agreed	20/07/2018	3	17/04/2019	3		Recruitment Finished
16/SS/0134	199690	A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY AND DETERMINE THE MAXIMUM TOLERATED DOSE OF PF-05230907 IN SUBJECTS	Number Agreed	3	Date Agreed	28/02/2019	0	28/02/2019	0		Recruitment Finished
16/SW/0120	201715	Study of the optimum duration of acoustic pulse thrombolysis procedure in the treatment of acute submassive pulmonary embolism	Number Agreed	8	Date Agreed	19/03/2020	0	01/05/2019	0		Withdrawn By Sponsor
16/WM/0448	212745	SHP620-303	Number Agreed	2	Date Agreed	19/05/2019	0	19/05/2019	0		Recruitment Finished
17/EE/0080	220727	A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen	Number Agreed	4	Date Agreed	31/10/2019	4	24/06/2019	4		Recruitment Finished
17/EM/0241	223736	Safety and efficacy analysis of FRED/FRED Jr embolic device in aneurysm treatment	Number Agreed	10	Date Agreed	31/12/2019	24	31/12/2019	24		Recruitment Finished
17/EM/0338	229242	A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors	Number Agreed	1	Date Agreed	22/11/2018	5	08/10/2019	5		Recruitment Finished
17/EM/0371	229496	Strategic Management to Optimize Response To Cardiac Resynchronization Therapy	Number Agreed	6	Date Agreed	31/10/2019	6	31/10/2019	6		Recruitment Finished
17/EM/0406	235483	PRTX-100 in ITP (PRTX-100-202)	Number Agreed	1	Date Agreed	30/07/2019	0	30/07/2019	0		Recruitment Finished
17/EM/0412	234907	CLNP023X2203 - Safety and efficacy study of LNP023 in IgA Nephropathy	Number Agreed	1	Date Agreed	30/04/2019	0	30/04/2019	0		Recruitment Finished
17/ES/0051	223060	PRO-105	Number Agreed	3	Date Agreed	30/09/2019	5	30/09/2019	5		Recruitment Finished
17/LO/0082	217324	PuraStat-002-VASC	Number Agreed	3	Date Agreed	30/09/2019	10	30/09/2019	10		Recruitment Finished
17/LO/0100	200545	A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens	Number Agreed	1	Date Agreed	28/02/2019	0	22/02/2019	0		Recruitment Finished
17/LO/0103	216784	A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety of TEV-48125 for the Prevention of Cluster Headache	Number Agreed	2	Date Agreed	19/12/2019	0	19/12/2019	0		Recruitment Finished
17/LO/0339	219974	MK-3475 (Pembrolizumab) Protocol 412: Study of Pembrolizumab given concomitantly with Chemoradiation and as maintenance therapy versus Chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma KEYNOTE 412	Number Agreed	4	Date Agreed	31/03/2019	7	31/03/2019	7		Recruitment Finished

17/LO/0525	221541	MERCURY 3	Number Agreed	1	Date Agreed	01/09/2019	1	01/09/2019	1		Recruitment Finished
17/LO/1018	224051	An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies	Number Agreed	2	Date Agreed	30/11/2019	5	01/02/2019	5		Recruitment Finished
17/LO/1247	228533	RANDOMIZED, OPEN LABEL, MULTICENTRE, PHASE 3 STUDY OF ROVALPITUZUMAB TESIRINE COMPARED WITH TOPOTECAN FOR SUBJECTS WITH ADVANCED OR METASTIC DLL3 SMALL CELL LUNG CANCER (SCLC) WHO HAVE FIRST DISEASE PROGRESSION DURING OR FOLLOWING FRONT LINE PLATINUM	Number Agreed	2	Date Agreed	29/03/2019	2	29/03/2019	2		Recruitment Finished
17/LO/1320	229845	Single-arm, phase II study of Luspatercept (ACE-536) in anemic patients with MPN-associated myelofibrosis.	Number Agreed	3	Date Agreed	28/02/2019	2	26/04/2019	2		Recruitment Finished
17/LO/1590	229278	A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenoc	Number Agreed	4	Date Agreed	01/10/2019	4	01/10/2019	4		Recruitment Finished
17/LO/1695	234684	BMN 270-301: Gene Therapy Study in Severe Haemophilia A Patients	Number Agreed	1	Date Agreed	26/09/2019	3	26/09/2019	3		Recruitment Finished
17/NE/0036	208636	SIR-Spheres for the treatment of cholangiocarcinoma - CANC 31007- SIRCCA	Number Agreed	6	Date Agreed	31/01/2019	6	31/01/2019	6		Recruitment Finished
17/NE/0174	224141	A PERFORMANCE EVALUATION STUDY OF ARQUER?S MCM5 ELISA TEST TO AID IN THE MONITORING OF BLADDER CANCER RECURRENCE	Number Agreed	10	Date Agreed	30/06/2019	23	30/06/2019	23		Recruitment Finished
17/NE/0300	225917	UM203	Number Agreed	18	Date Agreed	30/08/2019	17	30/08/2019	17		Recruitment Finished
17/SC/0201	209172	Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study.	Range Agreed	1	Date Agreed	01/09/2023	2	10/06/2019	2		Recruitment Finished
17/SC/0253	226685	MonarchE - 13Y-MC-JPCF	Number Agreed	5	Date Agreed	28/06/2019	11	28/06/2019	11		Recruitment Finished
17/SC/0291	226509	The DEFINE PCI study: Physiologic assessment of coronary stenosis following PCI.	Number Agreed	20	Date Agreed	31/03/2019	7	28/01/2019	7		Withdrawn By Sponsor
17/SC/0408	228262	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease.	Number Agreed	2	Date Agreed	03/04/2019	3	03/04/2019	3		Recruitment Finished
17/SC/0411	217829	A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100X (DNA PLASMID VECTORS EXPRESSING HPV-16 E6/E7, HPV-18 E6/E7) DELIVERED intramuscularly FOLLOWED BY EP WITH CELLECTRA® 5PSP FOR THE TREATMENT OF HISTOLOGICALLY PROVEN CIN2	Number Agreed	1	Date Agreed	22/09/2020	2	02/07/2019	2		Recruitment Finished
17/SC/0582	234404	A multicentre, open-label, long-term safety study of AR101 characterised oral desensitisation immunotherapy in subjects who participated in a prior AR101 study	Range Agreed	8	Date Agreed	31/12/2023	7	08/01/2019	7		Recruitment Finished
17/WM/0146	220303	Efficacy and Safety of E2609 in Subjects with Alzheimer?s Disease E2609-G000-301	Number Agreed	4	Date Agreed	01/02/2019	4	01/02/2019	4		Recruitment Finished
17/WM/0425	232819	A phase III trial evaluating the efficacy and safety of the SQ house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet in children and adolescents with HDM allergic asthma	Number Agreed	4	Date Agreed	21/05/2020	2	18/09/2019	2		Withdrawn By Host

17/WS/0120	225090	TRACE	Number Agreed	2	Date Agreed	01/09/2019	8	01/09/2019	8		Recruitment Finished
18/EE/0005	232671	Effect on HRCT Endpoints to Glucocorticoid in Pulmonary Sarcoidosis	Number Agreed	1	Date Agreed	31/05/2019	1	31/05/2019	1		Recruitment Finished
18/EM/0311	254008	A new treatment for rhinovirus-induced symptoms in smokers	Number Agreed	20	Date Agreed	01/08/2019	10	01/08/2019	10		Recruitment Finished
18/LO/0359	242661	GBT440-032: Phase 3 study in participants with sickle cell disease (HOPE Kids 2)	Number Agreed	2	Date Agreed	31/07/2019	0	31/07/2019	0		Recruitment Finished
18/LO/0430	241907	PRN1008 ? an Oral BTK Inhibitor in Patients with Relapsed ITP	Number Agreed	1	Date Agreed	31/08/2019	1	31/08/2019	1		Recruitment Finished
18/LO/0700	238068	A Phase 1/2 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects with Transfusion-Dependent $\beta$ Thalassemia.	Number Agreed	1	Date Agreed	31/12/2019	1	31/12/2019	1		Recruitment Finished
18/LO/0719	235423	A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients with C3 Glomerulopathy (C3G)	Number Agreed	5	Date Agreed	30/04/2019	1	30/04/2019	1		Recruitment Finished
18/LO/0995	244737	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with Advanced Endometrial Cancer	Number Agreed	4	Date Agreed	18/12/2019	7	18/12/2019	7		Recruitment Finished
18/LO/1289	245746	A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.	Number Agreed	3	Date Agreed	30/09/2020	1	04/03/2019	1		Withdrawn By Sponsor
18/LO/1461	245412	A Phase 2 Study of Sotatercept for the Treatment of PAH-PULSAR A011-09	Number Agreed	2	Date Agreed	30/09/2019	1	07/06/2019	1		Recruitment Finished
18/LO/2023	253130	A double-blind, randomised, placebo controlled, adaptive design study of the efficacy, safety and pharmacokinetics of NT-814 in female subjects with moderate to severe vasomotor symptoms associated with the menopause	Number Agreed	2	Date Agreed	27/12/2019	4	06/08/2019	4		Recruitment Finished
18/NE/0136	240494	CA2099DX_Ph3 Double Blind Liver Cancer Study using Nivolumab	Number Agreed	1	Date Agreed	24/09/2019	0	24/09/2019	0		Recruitment Finished
18/NW/0109	234734	PHIL evaluation in the endovascular treatment of intracranial dural AVF	Number Agreed	4	Date Agreed	31/12/2019	2	30/05/2019	2		Recruitment Finished
18/SC/0444	249450	A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular respo	Number Agreed	3	Date Agreed	31/12/2019	3	31/12/2019	3		Recruitment Finished
18/WA/0385	254760	NOVA	Number Agreed	5	Date Agreed	30/09/2019	0	30/09/2019	0		Recruitment Finished
18/WM/0006	225197	An Adaptive, Sequential Evaluation of Powered and Manual Circular Staplers in Left-Sided Colorectal Anastomoses	Range Agreed	3	Date Agreed	31/12/2019	3	31/12/2019	3		Recruitment Finished
18/YH/0099	241430	A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)	Number Agreed	5	Date Agreed	31/12/2019	4	31/12/2019	4		Withdrawn By Sponsor

18/YH/0090	241430	Generation 2 - CNP520 in participants at risk of Alzheimers	Number Agreed	25	Date Agreed	30/09/2019	12	30/09/2019	12		Withdrawn By Sponsor
18/YH/0136	214921	Biovotec- DermaRep Device	Number Agreed	5	Date Agreed	30/09/2019	4	30/09/2019	4		Recruitment Finished
19/SC/0031	257722	A randomised, placebo-controlled, double-blind, phase 1/2a study to evaluate the safety, reactogenicity, and immunogenicity of Ad26.RSV.preF in RSV-seronegative toddlers 12 to 24 months of age	Number Agreed	2	Date Agreed	30/05/2021	0	05/08/2019	0		Recruitment Finished